Sandi Tenza shares her journey with her son Sanda, diagnosed with haemophilia A, and the urgent need for awareness and ...

Dr. Ma. Leah Floirendo (left) and Dr. Jaymart Costillas (right) of Northern Mindanao Medical Center emphasize the importance ...

Qfitlia (fitusiran) is the first therapy for both hemophilia A or B, with or without inhibitors, available in the United ...

CSL Behring Austria today announced that the first haemophilia B patient in Austria was treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at the Comprehensive Care Center of the ...

The hemophilia treatment market in Japan is expected to witness steady growth during the forecast period, with a projected CAGR of 6.16% from 2025 to 2033. By the end of this period, the market is ...

Dr. Jonathan C. Roberts, associate medical director and research director of the Bleeding and Clotting Disorders Institute in ...

Despite the challenges, including what CSL CEO Paul McKenzie has described as a fragmented U.S. healthcare system, the blood ...

Belief BioMed (BBM) and Takeda China have announced China’s National Medical Products Administration's (NMPA) approval for ...

Microbleeds are relatively tiny undetectable bleeds occurring within the body It is crucial to find and treat these slow ...

Belief BioMed and Takeda China today jointly announced that BBM-H901, has been officially approved by the National Medical ...

The Ministry of Health, in cooperation with the Royal Medical Services, Saturday launched the national report on hemophilia ...

Soleo Health has been named the exclusive in-network specialty pharmacy for Qfitlia (fitusiran) by Sanofi, the first ...